Sabitlenmiş Tweet
Rodrigo Sánchez-Bayona
2.6K posts
Rodrigo Sánchez-Bayona
@Rodrosb
MD, PhD. Oncólogo | Unidad de Cáncer de Mama y Ginecológico Hospital 12 de Octubre (Spain) | ESMO Young Oncologists Committee Chair
Katılım Mayıs 2012
690 Takip Edilen4.6K Takipçiler
Rodrigo Sánchez-Bayona retweetledi
📰New international cohort study now out in @RO_GreenJournal 👉Radiation therapy management in BRCA1/2 carriers diagnosed with early #BreastCancer.
🔓pubmed.ncbi.nlm.nih.gov/41941938/
✍️@BlondeauxEva @LucaVisani2 @florencecoussy1 @dimeglio_anto @ava_kwong @ElisaAgostinett @JyotiBajpai01 @judithbalmana @AnnPartridgeMD @drkellyphillips @angela_toss @fedrophd @CuiWanda @vitti10 @DrShelleyHwang @MariyaRozenblit @BelaMrinakova @Prof_Nadia_H @Rodrosb @matteolambe @Icro_Meattini
English
📣The first results of the PROCURE Project are now published
🔬translational study, 26 Spanish institutions, 292 patients treated with TDXd
🧬pharmacogenomic analysis of UGT1A1 variants and TDXd-emergent AEs
🔜Ongoing cohort, stay tuned for more!
sciencedirect.com/science/articl…
English
Rodrigo Sánchez-Bayona retweetledi
📰 Today, #ESMOopen publishes the results of #PROCURE, a multicenter study involving more than 26 Spanish hospitals.
This analysis, conducted in 290 patients treated with TDXd, examines the role of variants in the UGT1A1 gene and their potential association with treatment toxicity, concluding that no differences in toxicity were observed among the different variants.
@Rodrosb, medical oncologist at @H12Octubre, member of the #SOLTIyoung committee and PI of PROCURE, further states that “the results open new lines of research on pneumonitis and specific biomarkers associated with this adverse event, in a cohort where the observed incidence was 11%.”
We have actively participated by centralizing data collection and statistical analysis for a collaborative project that already includes more than 300 patients from across Spain and continues to grow thanks to funding from an ISCIII FIS grant.
PROCURE also won the 2022 Health Research Award from the HNA Foundation and was recently a finalist among more than 170 nominations for the 2026 GEPAC Awards.
📰 Full article: sciencedirect.com/science/articl…
English
Science only advances through generating evidence, which can be sometimes frustrating.
Negative results do not mean wasting time. They mean lessons learned.
Expectations are not evidence.
Kudos to @PTarantinoMD 💪🏻
Paolo Tarantino@PTarantinoMD
Quoting @VincentRK: Clinical trials: Easy to criticize. Hard to do. Five years ago there was absolutely no data on ADC sequencing. There were two approved ADCs, T-DXd and SG With different target, linker, pharmacokinetics and slightly different payload structure. A clear unmet need in the post-T-DXd HER2+ setting. Could the two ADCs work one after the other and help patients with HER2+ MBC? Two ways to attempt answering this question. The faster, yet imperfect one: retrospective studies. We tried. We (and others) analyzed data from hundreds of real-world patients across the US. Presented and published our findings. academic.oup.com/jnci/article-a… Important questions, though, require quality answers. We concomitantly designed the trial. In a way to stop it early, after only 27 patients, if the answer was “not sufficient activity”, to ensure patients safety. We ran the trial, SATEEN. And can finally provide a prospective answer. Five years in the making. Huge efforts from research staff from multiple centers and from the sponsor. Generous participation by 27 patients. To obtain what I believe is a quality answer for an important clinical question. Not the answer we were hoping for. But one we can build on in the next years. Clinical trials: Easy to criticize. Hard to do.
English
Really proud of @H12Octubre Medical Oncology residents! Well done @LolaRNogueira
Lola R.Nogueira@LolaRNogueira
Great days at #ESMOBreast26 Berlin!! -Presenting our HER2DX clinical impact data📊 - Discussing lobular BC at the YO mentored clinical case session with Dr Nicholas Turner Thanks @myESMO and the YOC for the opportunity and the grant, but also to @RSanchezBayona for the support!
English
Rodrigo Sánchez-Bayona retweetledi
SOLTI team at #ESMOBreast26 🚀
Halfway through the congress, we’ve already shared great discussions, exchanged new ideas, and gathered plenty of learnings along the way.
Together we accelerate the future of cancer research.
#beSOLTI
#ESMOBreastCancer #AnnualCongress
English
Rodrigo Sánchez-Bayona retweetledi
Looking forward to a full day of @myESMO Young Oncologists activities at #ESMOBreast26 today — mentorship, clinical case discussions, and Vesalius talk
If you’re in Berlin, come join us for the discussions and connect with colleagues!
@myESMO
@DFCI_BreastOnc
@OncoAlert
English
Rodrigo Sánchez-Bayona retweetledi
10) Impact of HER2DX testing for multidisciplinary care in a comprehensive cancer center
English
Rodrigo Sánchez-Bayona retweetledi
👏 El Proyecto PROCURE de Rodrigo Sánchez-Bayona, oncólogo #H12O, finalista en los Premios @GEPAC_
✅ Analiza las variantes genómicas y el riesgo de toxicidad en pacientes con cáncer de mama, por el fármaco trastuzumab-deruxtecan.
⏩ c.madrid/8bdlw
#somosdel12
Español
Rodrigo Sánchez-Bayona retweetledi
AI is transforming oncology across research and clinical care
Join us for this @myESMO #YO4YO session focused on the critical evaluation and collaborative use of AI-powered tools
May 4 | 15:00–16:00 CEST
@OncoAlert @DFCI_BreastOnc @DanaFarber @KloftMaximilian @Rodrosb
ESMO - Eur. Oncology@myESMO
Are you interested in #AI-powered tools in #oncology? Join the #YO4YO Session w/ @GuiNaderMarta, @MaximilianKloft, @mihaela_aldea & @rdienstmann 📌 How to Evaluate and Collaborate on AI-Powered Tools in Oncology #ESMOYOC 📅4 May 15:00-16:00 CEST 🔗 ow.ly/M9gC50YQqbu
English
Rodrigo Sánchez-Bayona retweetledi
Rodrigo Sanchez Bayona on PROCURE Project Named Finalist at GEPAC Awards
@Rodrosb
oncodaily.com/voices/rodrigo…
#OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedTwitter
English
Rodrigo Sánchez-Bayona retweetledi
SOLTI NEXUS 2026: Ahead of time. Now a reality.
Over two days in Madrid, our annual event brought together more than 170 researchers, clinicians, and innovators to connect, exchange ideas, and explore how AI is transforming the future of breast cancer research and care.
Key highlights from the meeting included the growing impact of integrating clinical, molecular, and imaging data to enhance precision in treatment selection and to improve the design of clinical trials. In parallel, artificial intelligence is already beginning to optimize key aspects of trial execution, particularly in the identification of eligible patients.
Special thanks to our coordinators: Dr. Rodrigo Dienstmann (VHIO, Barcelona), Dr. Mafalda Oliveira (Hospital Vall d’Hebron / VHIO, Barcelona), Dr. Kino Gavila (IVO, Valencia), Dr. Rodrigo Sanchez Bayona (Hospital 12 de Octubre, Madrid)
A huge thank you to all our speakers: Dr. Alexandre Yazigi (Resilience), Dr. Ignacio H. Medrano (Savana), Dra. Raquel Pérez (VHIO, Barcelona), Dra. Federica Corso (Instituto Nazionale dei Tumori di Milano), Dr. Francisco Miguel Torres Grande, PhD, EMBA(Owkin), Dr. Max Hardy-Werbin (Trailing Health), Dr. Jose Aneiros-Fernández (HT Médica, Granada), Dra. Nuria Ribelles (Hospital Universitario Virgen de la Victoria, Málaga), and inigo de miguel (Universidad del País Vasco)
🤝 And to everyone who supported this initiative to advance breast cancer research: @pfizer_spain, @NovartisSpain, @GileadOncology, @roche_es, @MSDEspana, @drreddys, @AstraZenecaES, @DaiichiSankyoES, @Stemline, @ExactSciencesPO, @EliLillyandCo and @JazzPharma.
A new meeting point is here to stay and this is just the beginning. See you in 2027!
Read more 🔗 gruposolti.org/la-inteligenci…
#beSOLTI #SOLTINexus #breastcancer
English
Rodrigo Sánchez-Bayona retweetledi
Especial médicos🩺⚕️🏥👨🏻⚕️👩🏻⚕️.
Os dejo esta carta en JAMA. Se la pondré a mis alumnos en la próxima clase:
He elegido estas frases :
👇🏻⏰
«La medicina puede tener un significado extraordinario. Pero no puede sustituir el estar presente en tu propia vida. El mundo puede necesitarnos como médicos. Pero las personas que nos aman nos necesitan como nosotros mismos. Y ese es el rol que nadie más puede llenar.»
«La residencia refuerza la lección de que las instituciones están diseñadas para perdurar más allá de los individuos. En cambio, las familias no.»
«Creo en formar a la próxima generación. Creo en el significado de este trabajo. Lo que ha cambiado es mi disposición a absorber el desgaste sin cuestionarlo.»
«Ya no estoy dispuesta a seguir posponiendo la vida. La medicina exige mucho. Y nosotros damos profundamente. Pero no puede tomarlo todo.»
«El significado de mi trabajo es profundo. El significado de mi presencia en casa es irremplazable.»
Español
Rodrigo Sánchez-Bayona retweetledi
・"En HER2+, 2025 no solo redefine el tratamiento… redefine a quién tratamos".
・"Estamos pasando de tratar HER2… a tratar la biología detrás del HER2".
Dr. Rodrigo Sánchez-Bayona・"Lo mejor del año en cáncer de mama HER2+"
#BestofBreast2025Recap
#CancerdeMama
#Oncologia
Español
Rodrigo Sánchez-Bayona retweetledi
📍ASEICA y @_SEOM piden incorporar la biopsia líquida para avanzar hacia una oncología➕precisa y personalizada
Con motivo del Día de Innovación en Cáncer, ambas entidades presentan recomendaciones para su implantación progresiva en la práctica clínica
aseica.es/aseica-y-seom-…
Español
Rodrigo Sánchez-Bayona retweetledi
💉@ASEICAnews y @_SEOM impulsan incorporar la biopsia líquida para avanzar hacia una Oncología más precisa y personalizada con motivo del Día Mundial de la Innovación en Cáncer, que se celebra el 21 de abril.
🔬 La investigación ha permitido que esta tecnología haya alcanzado un grado de madurez suficiente como para comenzar su implementación asistencial, abriendo una nueva etapa en la Medicina de Precisión.
📰 Consulta la nota de prensa: seom.org/otros-servicio…
Español
Rodrigo Sánchez-Bayona retweetledi
Enhancing second-line treatment options and beyond is transforming the care of patients with HER2-positive metastatic breast cancer 🔬
Module 4 of BITES VI focuses on navigating current approved therapies and exploring promising emerging drugs, integrating the latest evidence to optimize patient outcomes in a rapidly evolving landscape.
Learn from Sonia Pernas (@SoniaPernas) (ICO, Barcelona) and join the discussion with Rodrigo Sánchez-Bayona (@Rodrosb) (H. 12 Octubre, Madrid) as they delve into treatment sequencing, novel agents, safety considerations, and strategies to maintain quality of life.
Stay at the forefront of breast cancer research with our e-learning platform #ScientificBites! 🔗 scientificbites.com/?lang=en
#beSOLTI #ScientificBitesSOLTI #breastcancer
English
Rodrigo Sánchez-Bayona retweetledi
📜Today we share the #Review "Pharmacogenomics in Solid Tumors: A Comprehensive Review of Genetic Variability and Its Clinical Implications"
👥by Rodrigo Sánchez-Bayona et al.
📎Link: mdpi.com/2072-6694/17/6…
Keywords: pharmacogenomics; personalized medicine; oncology
English
Rodrigo Sánchez-Bayona retweetledi
Hoy hemos celebrado la 3ª sesión del SOLTI Young – Development Program, con un debate muy enriquecedor sobre el tratamiento con inhibidores de CDK4/6 en cáncer de mama en estadio temprano.
La sesión ha contado con la participación de la Dra. Mafalda Oliveira (VHIO) y el Dr. Rodrigo Sanchez Bayona (Hospital 12 de Octubre), quienes han compartido su experiencia y perspectivas clínicas sobre este abordaje terapéutico.
Este programa cuenta con el apoyo de: @MSDEspana , @NovartisSpain , @pfizer_spain , @EliLillyandCo , @roche_es , @DaiichiSankyoES , @AstraZenecaES y @Stemline .
Español
Rodrigo Sánchez-Bayona retweetledi
